From: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
Multivariable analysis | Hazard ratio (95% CI) | p-value |
---|---|---|
Brain RT pre-afatinib | ||
No | 1 | |
Yes | 2.79 (0.93, 8.35) | 0.062 |
Starting dose | ||
30 mg | 1 | |
40 mg | 0.22 (0.07, 0.67) | 0.006 |